Stock SLDB SOLID BIOSCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Solid Biosciences Inc.

Equities

SLDB

US83422E2046

Real-time Estimate Cboe BZX
Other stock markets
 11:15:52 2024-04-26 am EDT 		5-day change 1st Jan Change
8.555 USD +0.18% Intraday chart for Solid Biosciences Inc. -1.26% +39.90%
Apr. 01 Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label MT
Apr. 01 Solid Biosciences Gets FDA Rare-Pediatric Designation for SGT-003 in Duchenne DJ

Evolution of the average Target Price on Solid Biosciences Inc.

Price target over the last 5 years

History of analyst recommendation changes

7ea7acba93c7ecf8cff224.VQgEuGb30VEaUuW-Pra7GtdGAHj4Q8tCOFsVtReOIbQ.ITk27S-WgGEjNrDEWv2JfaQEXy2sNqESdTNh4Ei-cPpnaUrCUL-zMiwI3Q~ed34eeda65fc4d6244cc580754cdbd1a

Analyst Recommendations on Solid Biosciences Inc.

William Blair Starts Solid Biosciences With Outperform Rating MT
Barclays Adjusts Price Target on Solid Biosciences to $21 From $8, Maintains Overweight Rating MT
Citigroup Starts Coverage on Solid Biosciences With Buy Rating, $16 Price Target MT
Piper Sandler Upgrades Solid Biosciences to Overweight From Neutral, Adjusts Price Target to $20 From $8 MT
HC Wainwright Adjusts Solid Biosciences' PT to $16 From $9, Maintains Buy Rating MT
Solid Biosciences Shares Fall After Surging Thursday; HC Wainwright Starts Coverage With Buy Rating MT
HC Wainwright Initiates Solid Biosciences With Buy Rating, Price Target is $9 MT
Cantor Fitzgerald Initiates Solid Biosciences at Overweight, $5 Price Target MT
Piper Sandler Adjusts Price Target on Solid Biosciences to $8 From $15, Maintains Neutral Rating MT
Barclays Adjusts Price Target on Solid Biosciences to $8 From $2, Maintains Overweight Rating MT
SVB Securities Downgrades Solid Biosciences to Market Perform From Outperform, Adjusts Price Target to $1 From $12 MT
Piper Sandler Adjusts Price Target on Solid Biosciences to $1 From $2, Maintains Neutral Rating MT
JPMorgan Upgrades Solid Biosciences to Neutral From Underweight MT
Chardan Research Adjusts Price Target on Solid Biosciences to $6 From $7, Reiterates Buy Rating MT
Piper Sandler Adjusts Price Target on Solid Biosciences to $2 From $5, Maintains Neutral Rating MT
SVB Leerink Adjusts Price Target on Solid Biosciences to $12 From $5, Keeps Outperform Rating MT
Piper Sandler Adjusts Solid Biosciences' Price Target to $5 From $6, Maintains Neutral Rating MT
Chardan Research Adjusts Price Target on Solid Biosciences to $7 From $17 on Duchenne Muscular Dystrophy Market Assumptions, Reiterates Buy Rating MT
SOLID BIOSCIENCES : Chardan Adjusts Price Target on Solid Biosciences to $17 From $20, Maintains Buy Rating MT
SOLID BIOSCIENCES : Piper Sandler Starts Solid Biosciences at Neutral With $6 Price Target MT
SOLID BIOSCIENCES : Jefferies Starts Solid Biosciences at Buy With $7 Price Target MT
SOLID BIOSCIENCES : Barclays Adjusts Price Target on Solid Biosciences to $8 From $13, Maintains Overweight Rating MT
SOLID BIOSCIENCES : Chardan Adjusts PT on Solid Biosciences to $20 From $12.50 on Increased Optimism After Clinical Trial Data, Maintains Buy Rating MT
SOLID BIOSCIENCES : Eversore ISI Adjusts Solid Biosciences PT to $9 From $4, Maintains In Line Rating MT
SOLID BIOSCIENCES : Credit Suisse Adjusts Price Target on Solid Biosciences to $8 From $7, Maintains Neutral Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.54 USD
Average target price
17.78 USD
Spread / Average Target
+108.17%
High Price Target
40 USD
Spread / Highest target
+368.38%
Low Price Target
6 USD
Spread / Lowest Target
-29.74%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Solid Biosciences Inc.

William Blair & Co.
Barclays
Citigroup
Piper Sandler
HC Wainwright
Cantor Fitzgerald
SVB Securities LLC
JPMorgan Chase
Chardan Research
SVB Leerink
Chardan
Jefferies & Co.
Credit Suisse
Evercore ISI

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. SLDB Stock
  4. Consensus Solid Biosciences Inc.